<DOC>
	<DOCNO>NCT00539994</DOCNO>
	<brief_summary>This Phase I/IIa randomize , double-blind , placebo-controlled study evaluate safety , tolerability , PK , efficacy Retapamulin ointment , 1 % applied twice daily 3 5 day anterior naris healthy adult subject nasally colonize S. aureus . Approximately 57 healthy subject nasal carrier S. aureus enrol stratify 2:1 ratio least 38 persistent carrier 19 intermittent carrier complete study . Each eligible subject participate three screen visit , treatment period , two follow-up visit . Each subject 's participation study approximately 6 10 week screen last follow-up visit . Subjects participate three screen visit determine S. aureus culture positivity colonization status .</brief_summary>
	<brief_title>Retapamulin Ointment Healthy Adults Nasally Colonized With Staphylococcus Aureus</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Male female subject age 18 65 , inclusive . A female eligible enter participate study nonpregnant , nonlactating : nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include premenopausal female document ( medical report verification ) hysterectomy double oophorectomy document tubal ligation postmenopausal female define amenorrheic great one year follicle stimulate hormone ( FSH ) level consistent menopause . childbearing potential negative pregnancy test screening . In addition , must willing abstain sexual intercourse must use nonhormone contraception IUD diaphragm spermicide , addition male partner use condom/spermicide . This criterion must follow least commencement last normal period prior first dose study medication screening ( whichever earlier ) completion followup procedure ( 33 day last dose study medication ) . Body weight ≥ 50 kg men ≥ 45 kg woman body mass index ( BMI ) 18.5 33 kg/m2 . The subject able understand comply requirement , instruction restriction list consent form . Signed date write informed consent prior admission study . Negative nasal culture S. aureus first screen visit . Negative nasal culture S. aureus second third screen visit . Concurrent treatment antimicrobial infection . MRSA decolonization attempt previous 6 month ( prior treatment MRSA infection exclusion criterion ) . Inability take medication nasally . Nasal surgery previous 3 month . Evidence active rhinitis , sinusitis , upper respiratory infection . Within judgment Principal Investigator Sponsor Medical Monitor , clinically significant hematologic , endocrine , cardiovascular , hepatic , renal , gastrointestinal , and/or pulmonary disorder ; predispose condition might interfere absorption , distribution , metabolism , and/or excretion drug ; clinically relevant abnormality identify physical examination , 12lead ECG , clinical laboratory screen . A single repeat clinical laboratory 12 lead ECG allow determine eligibility . The subject 's systolic BP outside range 90150mmHg , diastolic BP outside range 4595mmHg HR outside range 50100 bpm female subject 40100 bpm male subject . Subjects history allergy study drug drug class , history drug allergy , opinion investigator , contraindicate participation trial . In addition , heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . The use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St. John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator Sponsor medication interfere study procedure compromise subject safety . Use nasal medication strictly prohibit 7 day prior first screen visit 7 day prior 2nd screen visit final followup visit . Treatment investigational drug within 30 day five halflives ( whichever longer ) precede first dose study medication . The subject history alcohol substance abuse dependence within 12 month study : History regular alcohol consumption average &gt; 7 drinks/wk woman &gt; 14 drinks/wk men . 1 drink equivalent 12g alcohol = 5 oz ( 150ml ) wine 12oz ( 360ml ) beer 1.5 oz ( 45ml ) 80 proof distil spirit within six month screen . Positive Human Immunodeficiency Virus ( HIV ) antibody , hepatitis B virus surface antigen hepatitis C virus antibody screen . Donation blood excess 500 mL within 56 day prior dose . Note : This include plasma donation . The subject positive urine drug alcohol screen . The subject history illicit drug abuse unwilling refrain use illicit drug adhere protocolstated restriction participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Altabax</keyword>
	<keyword>SB-275833</keyword>
	<keyword>retapamulin</keyword>
	<keyword>nasal colonization</keyword>
	<keyword>PK</keyword>
	<keyword>tolerability</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>